Timeliness of EGFR/ALK Inhibitor Treatment and Survival in Lung Cancer: A Population-Based Analysis. Tanvetyanon T, Chen DT, Gray JE. Clin Lung Cancer 2024 Apr 30:S1525-7304(24)00078.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Tanvetyanon T, Chen DT, Gray JE. Timeliness of EGFR/ALK Inhibitor Treatment and Survival in Lung Cancer: A Population-Based Analysis. Clin Lung Cancer 2024 Apr 30:S1525-7304(24)00078.
PMID: 38825406